David Propper

Dr David Propper is a Clinical Professor specializing in pancreatic cancer research and translational medicine, with expertise in tumor-stromal interactions and reprogramming. His work integrates epigenetic targeting, immune therapies, and cytokine gene therapy in 3D laboratory models.

• Key Research Themes: Targeting Tumour Cells, Pancreatic Cancer, Tumour Microenvironment
• Major Funding: CRUK Stand Up To Cancer, Lustgarten Foundation, MRC, Barts Charity

Research Focus: Stromal reprogramming in pancreatic cancer, spanning mechanistic studies and phase I clinical trials. His work bridges laboratory models with translational applications, particularly in epigenetic modulation and immune-based therapies.

Publication Trends: Recent articles emphasize clinical trial design, chemotherapy optimization, and innovative immunotherapies (e.g., CAR-T cells) for pancreatic and colorectal cancers. Broad disciplines include Oncology, Immunology, and Clinical Trials, with subtopics like Stromal Targeting, Drug Combination Therapy, and Cytokine Signaling.

Collaborations & Grants: Funded by major institutions including Cancer Research UK and the Lustgarten Foundation, his research operates within the Centre for Tumour Microenvironment Research, focusing on global pancreatic cancer challenges.